Charter Life Sciences

Prevacept Infection Control is a clinical-stage company dedicated to developing and commercializing products aimed at preventing infections linked to indwelling catheters.

Xlumena, Inc. is a medical technology company specializing in the development of image-guided therapeutic endoscopy products. Founded in 2008 and located in Mountain View, California, the company focuses on creating innovative solutions for gastrointestinal and biliary conditions. Its product offerings include the AXIOS Stent and Delivery System, which is designed for treating pancreatic pseudocysts, and the NAVIX Access Device, also targeting this condition. Additionally, Xlumena develops a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a solution for hiatal hernia repair performed through the gastrointestinal lumen. In 2015, Xlumena became a subsidiary of Boston Scientific Corporation, further enhancing its capabilities in the medical device field.

Amaranth Medical, Inc. is a medical device company based in Mountain View, California, with additional research and manufacturing operations in Singapore and Silicon Valley. Founded in 2005, the company specializes in the development and manufacture of bioresorbable scaffolds intended for vascular and nonvascular applications. Its flagship product, FORTITUDE, is a bioresorbable coronary scaffold designed to assist arterial remodeling after interventional procedures. Amaranth Medical aims to transform interventional cardiology by offering scaffolds with advanced mechanical properties, promoting a new standard of care for stent interventions. The company's innovative approach focuses on creating scaffolds that gradually lose their mechanical strength while maintaining vessel functionality, allowing for flexibility without the complications associated with permanent metal implants. Through this commitment, Amaranth Medical strives to enhance patient health outcomes globally.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Xlumena, Inc. is a medical technology company specializing in the development of image-guided therapeutic endoscopy products. Founded in 2008 and located in Mountain View, California, the company focuses on creating innovative solutions for gastrointestinal and biliary conditions. Its product offerings include the AXIOS Stent and Delivery System, which is designed for treating pancreatic pseudocysts, and the NAVIX Access Device, also targeting this condition. Additionally, Xlumena develops a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a solution for hiatal hernia repair performed through the gastrointestinal lumen. In 2015, Xlumena became a subsidiary of Boston Scientific Corporation, further enhancing its capabilities in the medical device field.

Prevacept Infection Control is a clinical-stage company dedicated to developing and commercializing products aimed at preventing infections linked to indwelling catheters.

CoRepair is a company that develops a radio-frequency device system for the treatment of congestive heart failure.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.

Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels.

Visioneering Technologies, Inc., established in 2008 and based in Alpharetta, Georgia, is a medical device company specializing in the design, manufacture, and distribution of contact lenses. The company's flagship product, NaturalVue, is a multifocal contact lens designed to address presbyopia in adults and myopia in children. Visioneering Technologies operates in North America, Europe, and the Asia Pacific region, with a mission to enhance practitioner and patient experiences through innovative and differentiated optical solutions. The company holds fourteen issued patents worldwide, reflecting its commitment to advancing eye care.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

CoRepair is a company that develops a radio-frequency device system for the treatment of congestive heart failure.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Mirabilis Medical, Inc., established in 2004 and headquartered in Bothell, Washington, specializes in the design, development, manufacturing, distribution, installation, and servicing of ultrasound devices for non-invasive treatment of uterine fibroids. Their proprietary technology employs high-resolution ultrasound imaging for precise localization and non-invasive ablation of targeted tissue, eliminating the need for incisions or punctures.

KFx Medical specializes in the development and manufacturing of advanced soft tissue fixation implants specifically designed for orthopedic sports medicine. The company creates innovative products that facilitate tissue fixation, allowing for direct placement into bone, with or without sutures. These implants are utilized in various orthopedic surgical procedures, enabling surgeons to effectively reattach tissue in areas such as the shoulder, knee, foot, and ankle. KFx Medical collaborates with leading orthopedic surgeons to refine its technology and enhance surgical outcomes for patients.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

Amaranth Medical, Inc. is a medical device company based in Mountain View, California, with additional research and manufacturing operations in Singapore and Silicon Valley. Founded in 2005, the company specializes in the development and manufacture of bioresorbable scaffolds intended for vascular and nonvascular applications. Its flagship product, FORTITUDE, is a bioresorbable coronary scaffold designed to assist arterial remodeling after interventional procedures. Amaranth Medical aims to transform interventional cardiology by offering scaffolds with advanced mechanical properties, promoting a new standard of care for stent interventions. The company's innovative approach focuses on creating scaffolds that gradually lose their mechanical strength while maintaining vessel functionality, allowing for flexibility without the complications associated with permanent metal implants. Through this commitment, Amaranth Medical strives to enhance patient health outcomes globally.

Bullhorn, Inc. is a leading provider of staffing and recruiting software designed for startups, small to medium-sized businesses, and large enterprises. Founded in 1999 and headquartered in Boston, Massachusetts, the company offers a comprehensive suite of products, including applicant tracking systems, business intelligence tools, customer relationship management software, and onboarding solutions. These products facilitate the automation of the recruitment lifecycle, aiding in candidate sourcing, placement, and time and expense management, while also streamlining payment and billing processes. Bullhorn serves a diverse range of sectors, including professional staffing, healthcare, executive search, commercial, and nonprofit organizations. The company has expanded its presence internationally, with offices in the United Kingdom, the Netherlands, Germany, Australia, and various locations in the United States and beyond, reflecting its commitment to delivering innovative solutions tailored to the needs of the staffing industry.

Kereos, Inc. is a biopharmaceutical company based in St. Louis, Missouri, specializing in the development of nanoscale drug delivery technologies and molecular imaging agents aimed at the detection and treatment of cancer and cardiovascular diseases. Founded in 1999, Kereos focuses on targeted delivery systems that enhance the effectiveness of therapeutic compounds, including existing drugs and novel candidates, particularly those that are too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001 and KER-1002, both cancer therapeutics utilizing natural products with demonstrated anti-tumor efficacy, and KER-1003, which targets angiogenesis. Additionally, Kereos offers diagnostic applications, such as KER 0001, an imaging platform for detecting angiogenesis. The company is also engaged in developing partnerships with pharmaceutical and imaging firms to advance its molecular imaging systems and cardiovascular disease MRI agents, thereby broadening its impact in the healthcare sector.

KFx Medical specializes in the development and manufacturing of advanced soft tissue fixation implants specifically designed for orthopedic sports medicine. The company creates innovative products that facilitate tissue fixation, allowing for direct placement into bone, with or without sutures. These implants are utilized in various orthopedic surgical procedures, enabling surgeons to effectively reattach tissue in areas such as the shoulder, knee, foot, and ankle. KFx Medical collaborates with leading orthopedic surgeons to refine its technology and enhance surgical outcomes for patients.